Document Detail

Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
MedLine Citation:
PMID:  22420526     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: Besifloxacin ophthalmic suspension 0.6% given thrice daily for 5 days is safe and effective in the treatment of patients with bacterial conjunctivitis. This study evaluated the safety and efficacy of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days compared with vehicle in the treatment of bacterial conjunctivitis.
STUDY DESIGN: This was a multicenter, double-masked, randomized, vehicle-controlled, parallel-group study.
METHODS: A total of 474 patients aged ≥1 year with bacterial conjunctivitis were randomized in a 1 : 1 ratio to receive either besifloxacin ophthalmic suspension 0.6% or vehicle administered twice daily for 3 days. There were three study visits: day 1 (the baseline visit), day 4/5 (visit 2), and day 7 ± 1 (visit 3). The co-primary efficacy endpoints were bacterial eradication and clinical resolution at day 4/5 in designated study eyes of patients with culture-confirmed bacterial conjunctivitis. Secondary efficacy endpoints were bacterial eradication and clinical resolution at day 7 ± 1, individual clinical outcomes of ocular discharge and bulbar conjunctival injection at all visits; and microbial and clinical outcomes for overall bacterial species and individual Gram-positive and Gram-negative bacterial species at each follow-up visit. Safety endpoints included adverse events (AEs), changes in visual acuity and biomicroscopy findings at each visit, and changes in ophthalmoscopy findings at day 7 ± 1.
RESULTS: Bacterial eradication and clinical resolution rates were significantly higher in the besifloxacin group than in the vehicle group (115/135 [85.2%] vs 77/141 [54.6%], p < 0.001, and 89/135 [65.9%] vs 62/141 [44.0%], p < 0.001, respectively) at day 4/5. Rates of bacterial eradication continued to be significantly greater in the besifloxacin group (115/135 [85.2%] vs 91/141 [64.5%], respectively; p < 0.001) at day 7 ± 1; however, the rates of clinical resolution did not differ significantly between the groups (103/135 [76.3%] and 94/141 [66.7%], p = 0.209) at this visit. Ocular discharge and bulbar conjunctival injection at each visit were consistent with the primary outcomes. Clinical resolution and bacterial eradication with Gram-positive or Gram-negative organisms were consistent with the overall findings. All AEs in both groups were of mild or moderate severity and were considered unrelated to the treatment.
CONCLUSION: Treatment with besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days was effective and safe in adults and children with bacterial conjunctivitis.
CLINICAL TRIAL REGISTRATION: Registered at as NCT00972777.
Jesse DeLeon; Bruce E Silverstein; Catherine Allaire; Lynne S Gearinger; Kirk M Bateman; Timothy W Morris; Timothy L Comstock
Related Documents :
6731326 - Göteborg metoprolol trial: design, patient characteristics and conduct.
20797926 - Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas.
10471456 - The effect of spironolactone on morbidity and mortality in patients with severe heart f...
2446056 - Ketanserin versus nifedipine in the treatment of essential hypertension in patients ove...
9204616 - Treatment of active gastroesophageal variceal bleeding with terlipressin or hemostatic ...
11668406 - Endoscopic factors predisposing to rebleeding following endoscopic hemostasis in bleedi...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical drug investigation     Volume:  32     ISSN:  1179-1918     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-16     Completed Date:  2012-08-10     Revised Date:  2014-09-23    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  303-17     Citation Subset:  IM    
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Ophthalmic
Anti-Bacterial Agents / administration & dosage*,  adverse effects,  therapeutic use
Azepines / administration & dosage*,  adverse effects,  therapeutic use
Child, Preschool
Conjunctivitis, Bacterial / drug therapy*,  microbiology
Double-Blind Method
Fluoroquinolones / administration & dosage*,  adverse effects,  therapeutic use
Follow-Up Studies
Gram-Negative Bacteria / isolation & purification
Gram-Positive Bacteria / isolation & purification
Middle Aged
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Azepines; 0/Fluoroquinolones; 0/Suspensions; BFE2NBZ7NX/7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-Term Hepatic Allograft Acceptance Based on CD40 Blockade by ASKP1240 in Nonhuman Primates.
Next Document:  Provisional unicentric experience with an electronic incident reporting form in pediatric anesthesia...